Evidence-based goals when treating MASLD and MASH
| Goal | Description |
| Resolution of MASH | Achieving the absence or significant reduction of liver inflammation and elimination of hepatocyte ballooning without worsening fibrosis, assessed through liver biopsy or non-invasive tests. |
| Regression of MASLD | Targeting measurable decreases in liver fat accumulation, inflammation, or fibrosis to improve liver health and function. |
| Prevention of fibrosis progression | Crucial for reducing liver-related morbidity and mortality, as advanced fibrosis significantly increases the risk of severe liver complications and death. |
| Reduction of cardiometabolic mortality | Improving overall metabolic health and reducing cardiovascular risk are vital aspects of MASLD management. This involves treating associated conditions like obesity, dyslipidaemia, hypertension and T2D. |
MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; T2D, type 2 diabetes mellitus.